MOB-015 is a new topical treatment for onychomycosis with fungicidal, keratolytic and emollient properties. A clinical Phase II trial is ongoing.
Moberg Pharmas patent-pending formulation technology facilitates high concentrations of a fungicidal substance to be transported in and through nail tissue. As MOB-015 is applied locally, the side effects associated with oral treatment are avoided. MOB-015 also has keratolytic and emollient properties, thus facilitating fast and visible improvement in the nail.
Nail fungus (onychomycosis), which can affect both toe- and fingernails, chiefly manifests itself in thickening and discoloration of the nails. Nail fungus is hard to treat, and the treatment time is often long, as it takes up to a year for a healthy new nail to grow out. The disease is common, affecting about 100 million patients in Europe and North America. Prevalence is about 10% in the general population and over 25% in the over-50s. About 40% of all patients with psoriasis are also affected by changes in the nail. Based on IMS data the total market is estimated to in excess of $1.4bn, despite the great majority of those infected being untreated.
Phase II trial ongoing.